Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to -$2.4 million.

  • Neurocrine Biosciences' Capital Expenditures fell 13287.67% to -$2.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $34.0 million, marking a year-over-year decrease of 1099.48%. This contributed to the annual value of $34.0 million for FY2025, which is 1099.48% down from last year.
  • According to the latest figures from Q4 2025, Neurocrine Biosciences' Capital Expenditures is -$2.4 million, which was down 13287.67% from $13.2 million recorded in Q3 2025.
  • Neurocrine Biosciences' Capital Expenditures' 5-year high stood at $13.2 million during Q3 2025, with a 5-year trough of -$2.4 million in Q4 2025.
  • Over the past 4 years, Neurocrine Biosciences' median Capital Expenditures value was $8.1 million (recorded in 2024), while the average stood at $8.1 million.
  • As far as peak fluctuations go, Neurocrine Biosciences' Capital Expenditures surged by 24615.38% in 2021, and later crashed by 13287.67% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' Capital Expenditures (Quarter) stood at $4.5 million in 2021, then rose by 20.0% to $5.4 million in 2023, then skyrocketed by 35.19% to $7.3 million in 2024, then plummeted by 132.88% to -$2.4 million in 2025.
  • Its last three reported values are -$2.4 million in Q4 2025, $13.2 million for Q3 2025, and $12.5 million during Q2 2025.